Ilaris (canakinumab) for injection
TRIKAFTA is a prescription medicine used for the treatment of Periodic fever syndromes, Cryopyrin-associated periodic syndromes, Tumour necrosis factor receptor associated periodic syndrome (TRAPS), Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), Familial Mediterranean fever (FMF), Still’s disease, Gouty arthritis. Brand name: Ilaris 150 mg powder for solution for injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
Ilaris 150 mg powder for solution for injection
Canakinumab may help to lessen the symptoms, such as rash, joint/muscle pain, fever, eye redness, and tiredness. Canakinumab is also used to treat a type of rheumatoid arthritis in children (systemic juvenile idiopathic arthritis-SJIA), as well as Still's Disease in adults.
Ilaris is a medicine for treating the following inflammatory conditions:
4 types of periodic fever syndromes (diseases marked by recurring inflammation and fever) in adults and children aged 2 and above:
cryopyrin-associated periodic syndromes (CAPS);
tumour necrosis factor receptor associated periodic syndrome (TRAPS);
hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD);
familial mediterranean fever (FMF);
Still’s disease, a rare disease causing inflammation of joints as well as rash and fever (in adults and children aged 2 and above);
Gouty arthritis, painful inflammation of the joints caused by deposit of urate crystals (in adults).
Ilaris contains the active substance canakinumab.
Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the U.S. Food and Drug Administration (FDA) in June 2009, and by the European Medicines Agency (EMA) in October 2009. CAPS is a spectrum of autoinflammatory syndromes including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle–Wells syndrome (MWS), and Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
In September 2016, the FDA approved the use of canakinumab for three additional rare and serious auto-inflammatory diseases: tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial mediterranean fever (FMF).
In June 2020, canakinumab was approved in the United States for the indication to treat active Still’s disease, including adult-onset Still’s disease.
In the European Union, canakinumab is indicated for autoinflammatory periodic fever syndromes, cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), familial Mediterranean fever (FMF), Still’s disease, and gouty arthritis.
In August 2023, the FDA expanded coverage to cover the treatment of gout flares.
Drug (Brand / Generic): Ilaris / canakinumab
Current Indications: diseases marked by recurring inflammation and fever
Marketed by:: Novartis Europharm Limited
Approval Date: 23/10/2009
Dosage forms and strengths of Ilaris 150 mg powder for solution for injection
One vial contains 150 mg of canakinumab.
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ Ilaris (canakinumab) for injection ”. Confirmation of the order for Ilaris (canakinumab) for injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – Ilaris
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha.
Ilaris Sourcing & Delivery
Alleviare India specializes in sourcing and supplying Ilaris, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of Ilaris in India.
How much does Ilaris cost in the India?
Kindly reach out to us for Ilaris (canakinumab) for injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import Ilaris to India?
To import canakinumab Ilaris, patients or government hospitals can place an order on behalf of the patients. The following documentation is required for the import process:
Valid prescription from a qualified doctor.
Patients’ diagnostic reports.
Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
Valid prescription from the doctor.
Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is Ilaris available in India?
Ilaris canakinumab is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of Ilaris (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for Ilaris availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is canakinumab available in India?
Jun 18, 2009 Approval New Biological Therapy Ilaris Approved In US To Treat Children And Adults With CAPS, A Serious Life-Long Auto-Inflammatory Disease
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand Ilaris (canakinumab) for injection . The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to Ilaris (canakinumab) for injection , they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
